Compare VVOS & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VVOS | LGVN |
|---|---|---|
| Founded | 2016 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.4M | 17.6M |
| IPO Year | 2020 | 2021 |
| Metric | VVOS | LGVN |
|---|---|---|
| Price | $2.05 | $0.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $6.75 | $6.50 |
| AVG Volume (30 Days) | 116.0K | ★ 457.0K |
| Earning Date | 11-19-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $17,317,000.00 | $1,437,000.00 |
| Revenue This Year | $19.45 | N/A |
| Revenue Next Year | $70.80 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 18.76 | N/A |
| 52 Week Low | $1.98 | $0.59 |
| 52 Week High | $7.95 | $2.24 |
| Indicator | VVOS | LGVN |
|---|---|---|
| Relative Strength Index (RSI) | 33.84 | 40.58 |
| Support Level | $2.03 | $0.60 |
| Resistance Level | $2.33 | $0.69 |
| Average True Range (ATR) | 0.16 | 0.05 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 4.35 | 37.03 |
Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.